OTCMKTS:CYYNF Cynata Therapeutics (CYYNF) Stock Price, News & Analysis → Trump conviction scandal exposed (From Porter & Company) (Ad) Free CYYNF Stock Alerts $0.19 0.00 (0.00%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$0.19▼$0.1950-Day Range$0.11▼$0.1952-Week Range$0.11▼$0.19VolumeN/AAverage Volume10 shsMarket Capitalization$27.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartStock AnalysisChart Get Cynata Therapeutics alerts: Email Address Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About Cynata Therapeutics Stock (OTCMKTS:CYYNF)Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, brain cancer, sepsis, acute respiratory distress syndrome, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.Read More CYYNF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYYNF Stock News HeadlinesMarch 6, 2024 | msn.comCynata Therapeutics treats first patient in aGvHD drug trialMarch 4, 2024 | finance.yahoo.comFirst Patient Treated in Phase 2 GvHD TrialAugust 14, 2023 | markets.businessinsider.comVYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 11, 2023 | markets.businessinsider.comJefferies Reaffirms Their Buy Rating on C4 Therapeutics (CCCC)August 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: CymaBay Therapeutics (CBAY) and Vor Biopharma (VOR)August 10, 2023 | technews.tmcnet.comTScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJuly 19, 2023 | benzinga.comCyteir Therapeutics 10% Owner Sold $106K In Company StockMay 2, 2023 | finance.yahoo.comDimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior AdvisorNovember 16, 2022 | finance.yahoo.comWe Think Shareholders Are Less Likely To Approve A Pay Rise For Cynata Therapeutics Limited's (ASX:CYP) CEO For NowNovember 4, 2022 | finance.yahoo.comLUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney TransplantationSeptember 26, 2022 | benzinga.comCynata Therapeutics Stock (OTC:CYYNF), Earnings Estimates, EPS, and RevenueMay 26, 2022 | finance.yahoo.comUS FDA Clears IND for Cynata's Phase 2 Clinical Trial of CYP-001 in GvHDJanuary 14, 2022 | finance.yahoo.comWe Think Cynata Therapeutics (ASX:CYP) Can Afford To Drive Business GrowthDecember 29, 2021 | msn.comHere’s why the Cynata (ASX:CYP) share price is rising todaySeptember 30, 2021 | finance.yahoo.comCynata Enters into a New Strategic Partnership with FujifilmSee More Headlines Receive CYYNF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cynata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/16/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Sanitary paper products Sub-IndustryN/A Current SymbolOTCMKTS:CYYNF CUSIPN/A CIKN/A Webwww.cynata.com Phone61 3 9824 5254FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares143,280,000Free FloatN/AMarket Cap$27.22 million OptionableNot Optionable Beta0.43 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Kilian KellyMD, CEO & DirectorDr. Jolanta AireyChief Medical OfficerMr. Peter Gordon Webse B.Bus (Age 61)FCIS, FCPA, FGIA, M.A.I.C.D., Company Secretary Comp: $90.84kKey CompetitorsJushiOTCMKTS:JUSHFCyteir TherapeuticsNASDAQ:CYTTAffimedNASDAQ:AFMDInterCureNASDAQ:INCRCytomX TherapeuticsNASDAQ:CTMXView All Competitors CYYNF Stock Analysis - Frequently Asked Questions How have CYYNF shares performed in 2024? Cynata Therapeutics' stock was trading at $0.0720 at the beginning of the year. Since then, CYYNF shares have increased by 163.9% and is now trading at $0.19. View the best growth stocks for 2024 here. How do I buy shares of Cynata Therapeutics? Shares of CYYNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CYYNF) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredBUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. ...Stansberry Research | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cynata Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Cynata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.